On the public citation graph
Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis
0 signed · 161 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamaoncol.2017.3064openalex-snapshot
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
inferredcites →https://doi.org/10.1016/j.cct.2015.09.002openalex-snapshot
Meta-analysis in clinical trials revisited
inferredcites →https://doi.org/10.1016/j.cgh.2016.09.017openalex-snapshot
Nivolumab-Induced Colitis Treated by Infliximab
inferredcites →https://doi.org/10.1016/j.lungcan.2016.07.001openalex-snapshot
Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report
inferredcites →https://doi.org/10.1016/s0140-6736(14)60958-2openalex-snapshot
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
inferredcites →https://doi.org/10.1016/s0140-6736(15)01281-7openalex-snapshot
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(16)00587-0openalex-snapshot
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(16)32455-2openalex-snapshot
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(13)70381-4openalex-snapshot
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(15)70076-8openalex-snapshot
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30126-7openalex-snapshot
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30167-xopenalex-snapshot
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30364-3openalex-snapshot
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30231-0openalex-snapshot
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30446-1openalex-snapshot
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
inferredcites →https://doi.org/10.1038/nrclinonc.2016.58openalex-snapshot
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
inferredcites →https://doi.org/10.1056/nejmoa1200694openalex-snapshot
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
inferredcites →https://doi.org/10.1056/nejmoa1302369openalex-snapshot
Nivolumab plus Ipilimumab in Advanced Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1412082openalex-snapshot
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
inferredcites →https://doi.org/10.1056/nejmoa1414428openalex-snapshot
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1503093openalex-snapshot
Pembrolizumab versus Ipilimumab in Advanced Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1504627openalex-snapshot
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1510665openalex-snapshot
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1602252openalex-snapshot
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
inferredcites →https://doi.org/10.1056/nejmoa1606774openalex-snapshot
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1611299openalex-snapshot
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
inferredcites →https://doi.org/10.1056/nejmoa1709684openalex-snapshot
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
inferredcites →https://doi.org/10.1056/nejmra1703481openalex-snapshot
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
inferredcites →https://doi.org/10.1084/jem.183.6.2533openalex-snapshot
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.
inferredcites →https://doi.org/10.1084/jem.20051776openalex-snapshot
Tissue expression of PD-L1 mediates peripheral T cell tolerance
inferredcites →https://doi.org/10.1097/cji.0b013e31828eed39openalex-snapshot
Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
inferredcites →https://doi.org/10.1097/md.0000000000008931openalex-snapshot
Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients
inferredcites →https://doi.org/10.1097/rlu.0000000000000940openalex-snapshot
Pancreatitis Secondary to Anti–Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT
inferredcites →https://doi.org/10.1111/apt.13281openalex-snapshot
Systematic review: colitis associated with anti‐ CTLA ‐4 therapy
inferredcites →https://doi.org/10.1111/liv.13746openalex-snapshot
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
inferredcites →https://doi.org/10.1126/science.270.5238.985openalex-snapshot
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
inferredcites →https://doi.org/10.1136/bmj.b2700openalex-snapshot
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
inferredcites →https://doi.org/10.1136/bmj.d5928openalex-snapshot
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-3080openalex-snapshot
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
inferredcites →https://doi.org/10.1200/jco.2014.60.0379openalex-snapshot
Toxicities of Immunotherapy for the Practitioner
inferredcites →https://doi.org/10.1200/jco.2015.65.9789openalex-snapshot
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
inferredcites →https://doi.org/10.1200/jco.2016.66.9929openalex-snapshot
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.2217/fon.15.222openalex-snapshot
Risk of Endocrine Complications in Cancer Patients Treated with Immune Check Point Inhibitors: A Meta-Analysis
inferredcites →https://doi.org/10.2217/imt.15.87openalex-snapshot
Risk of Gastrointestinal Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis
inferredcites →https://doi.org/10.2337/dbi18-0002openalex-snapshot
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4748520openalex-extracted
Pancreatitis in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/ejhf.2289openalex-snapshot
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis
inferred← citeshttps://doi.org/10.1002/iju5.12633openalex-snapshot
Pancreatitis as immune‐related adverse event during pembrolizumab therapy for multiple lung metastases from renal pelvic cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-41008-7_14openalex-snapshot
Hepatobiliary Adverse Events
inferred← citeshttps://doi.org/10.1007/978-3-030-56824-5_10openalex-snapshot
Non-Rheumatic Immune-Related Adverse Events
inferred← citeshttps://doi.org/10.1007/978-3-030-79308-1_13openalex-snapshot
Hepatobiliary and Pancreatic Adverse Events
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_348-1openalex-snapshot
Endocrine Toxicities Related to Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-031-00241-0_12openalex-snapshot
Pancreas and Gallbladder
inferred← citeshttps://doi.org/10.1007/978-3-032-00775-9_348openalex-snapshot
Endocrine Toxicities Related to Immunotherapy
inferred← citeshttps://doi.org/10.1007/s00108-025-01888-3openalex-snapshot
Pankreatitis durch Medikamente – Medikamente zur Behandlung der Pankreatitis
inferred← citeshttps://doi.org/10.1007/s00125-022-05666-wopenalex-snapshot
When therapeutic drugs lead to diabetes
inferred← citeshttps://doi.org/10.1007/s00261-025-04994-wopenalex-snapshot
Case of simultaneous occurrence of hepatitis, cholangitis, and pancreatitis as immune-related adverse events induced by immune checkpoint inhibitor therapy: a case report
inferred← citeshttps://doi.org/10.1007/s00262-022-03295-1openalex-snapshot
Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification
inferred← citeshttps://doi.org/10.1007/s00535-024-02083-1openalex-snapshot
Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy
inferred← citeshttps://doi.org/10.1007/s00535-026-02389-2openalex-snapshot
Immune checkpoint inhibitor-related pancreatitis: a comprehensive review of epidemiology, pathophysiology, and management
inferred← citeshttps://doi.org/10.1007/s10620-026-10120-7openalex-snapshot
Type 3 Autoimmune Pancreatitis: What Do We Know So Far?
inferred← citeshttps://doi.org/10.1007/s10637-024-01452-0openalex-snapshot
Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis
inferred← citeshttps://doi.org/10.1007/s10637-025-01517-8openalex-snapshot
Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis
inferred← citeshttps://doi.org/10.1007/s10753-021-01430-1openalex-snapshot
PD-1/PDL1 Blockade Exacerbates Pancreatic Damage and Immune Response in a Mouse Model of Acute Pancreatitis
inferred← citeshttps://doi.org/10.1007/s11523-019-00694-wopenalex-snapshot
Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review
inferred← citeshttps://doi.org/10.1007/s11523-024-01098-1openalex-snapshot
Pancreatitis in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1007/s11894-023-00885-6openalex-snapshot
Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis
inferred← citeshttps://doi.org/10.1007/s12094-024-03573-7openalex-snapshot
Clinical characteristics and prognosis of pancreatitis associated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s13181-021-00833-8openalex-snapshot
A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/b978-0-443-23947-2.00067-9openalex-snapshot
Autoimmune pancreatitis
inferred← citeshttps://doi.org/10.1016/b978-0-443-41638-5.00006-5openalex-snapshot
Immunotherapy and gastrointestinal-related side effects in patients with cancers
inferred← citeshttps://doi.org/10.1016/j.acra.2022.03.007openalex-snapshot
Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review
inferred← citeshttps://doi.org/10.1016/j.biopha.2022.113839openalex-snapshot
The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy
inferred← citeshttps://doi.org/10.1016/j.clcc.2023.12.003openalex-snapshot
Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/j.clinimag.2020.04.007openalex-snapshot
A review of the imaging manifestations of immune check point inhibitor toxicities
inferred← citeshttps://doi.org/10.1016/j.ejca.2023.03.025openalex-snapshot
Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus
inferred← citeshttps://doi.org/10.1016/j.ejrad.2020.109250openalex-snapshot
Imaging findings of immune checkpoint inhibitor associated pancreatitis
inferred← citeshttps://doi.org/10.1016/j.micres.2022.127105openalex-snapshot
A systematic review and meta-analysis of the IgA seroprevalence in COVID-19 patients: Is there a role for IgA in COVID-19 diagnosis or severity?
inferred← citeshttps://doi.org/10.1016/j.mmm.2022.06.004openalex-snapshot
Diabètes pharmaco-induits : quatre classes médicamenteuses au cœur de notre pratique clinique
inferred← citeshttps://doi.org/10.1016/j.pathol.2022.04.010openalex-snapshot
IgG4-related autoimmune pancreatitis-like mass-forming lesion on a background of immune checkpoint inhibitor immunotherapy
inferred← citeshttps://doi.org/10.1021/acsomega.9b02386openalex-snapshot
Chlorin e6-Conjugated and PEGylated Immune Checkpoint Inhibitor Nanocomposites for Pulmonary Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1055/a-1735-3864openalex-snapshot
S3-Leitlinie Pankreatitis – Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – September 2021 – AWMF Registernummer 021-003
inferred← citeshttps://doi.org/10.1055/a-2286-0469openalex-snapshot
Akute Pankreatitis: Fortschritt durch Zurückhaltung?
inferred← citeshttps://doi.org/10.1080/14740338.2025.2486311openalex-snapshot
Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database
inferred← citeshttps://doi.org/10.1080/14740338.2025.2493783openalex-snapshot
Pancreatic adverse events induced by immune checkpoint inhibitors: a real-world observational study
inferred← citeshttps://doi.org/10.1080/14796694.2026.2654735openalex-snapshot
GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence
inferred← citeshttps://doi.org/10.1080/1750743x.2025.2516995openalex-snapshot
Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy
inferred← citeshttps://doi.org/10.1080/24725625.2021.1899444openalex-snapshot
Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab
inferred← citeshttps://doi.org/10.1093/gastro/goae064openalex-snapshot
Asymptomatic pancreatic enlargement without pancreatic enzyme elevation: a rare case of immune checkpoint inhibitor-associated pancreatitis
inferred← citeshttps://doi.org/10.1093/oncolo/oyad150openalex-snapshot
Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1097/cji.0000000000000472openalex-snapshot
Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion
inferred← citeshttps://doi.org/10.1097/md.0000000000050285openalex-snapshot
Analysis of a case of immune-related pancreatitis induced by anti-PD-1 antibody therapy for gastric cancer
inferred← citeshttps://doi.org/10.1097/mpa.0000000000002337openalex-snapshot
Incidence and Effect Duration of Immune Checkpoint Inhibitor-Related Pancreas Adverse Events
inferred← citeshttps://doi.org/10.1097/mpa.0000000000002582openalex-snapshot
Immune Checkpoint Inhibitor–Induced Pancreatic Injury: An Emerging Form of Immune-Mediated Pancreatitis
inferred← citeshttps://doi.org/10.1097/pap.0000000000000346openalex-snapshot
Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review
inferred← citeshttps://doi.org/10.1097/pap.0000000000000401openalex-snapshot
Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review
inferred← citeshttps://doi.org/10.1097/pas.0000000000002398openalex-snapshot
Clinicopathologic Characteristics of Immune Checkpoint Inhibitor-related Pancreatitis
inferred← citeshttps://doi.org/10.1097/rct.0000000000001315openalex-snapshot
A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know
inferred← citeshttps://doi.org/10.1097/sga.0000000000000889openalex-snapshot
Simultaneous Development of Pemrolizumab-Associated Pancreatitis and Hemorrhagic Gastritis
inferred← citeshttps://doi.org/10.1101/2024.02.15.580302openalex-snapshot
Tissue-resident regulatory T cells exert dualistic anti-tumour and pro-repair function in the exocrine pancreas
inferred← citeshttps://doi.org/10.1111/1759-7714.13990openalex-snapshot
Clinical‐radiological characteristics and intestinal microbiota in patients with pancreatic immune‐related adverse events
inferred← citeshttps://doi.org/10.1111/apt.17980openalex-snapshot
Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1111/jdv.20384openalex-snapshot
Immune checkpoint inhibitor‐induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy—A multicentre analysis
inferred← citeshttps://doi.org/10.1136/jitc-2024-009742openalex-snapshot
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events
inferred← citeshttps://doi.org/10.1155/crgm/5519015openalex-snapshot
Endoscopic Ultrasound With Fine Needle Biopsy Confirming a Diagnosis of Immune Checkpoint Inhibitor‐Related Type 3 Autoimmune Pancreatitis
inferred← citeshttps://doi.org/10.1159/000533904openalex-snapshot
Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab Use
inferred← citeshttps://doi.org/10.1177/10781552241245332openalex-snapshot
Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemia
inferred← citeshttps://doi.org/10.1177/10781552251348662openalex-snapshot
Characteristics and outcomes of low-grade and high-grade pancreatic immune-related adverse events at a single center
inferred← citeshttps://doi.org/10.1186/s40644-021-00440-4openalex-snapshot
PET/CT variants and pitfalls in malignant melanoma
inferred← citeshttps://doi.org/10.1259/bjro.20210027openalex-snapshot
Gastrointestinal adverse events of immunotherapy
inferred← citeshttps://doi.org/10.12998/wjcc.v8.i16.3411openalex-snapshot
Steroid-responsive pancreatitides
inferred← citeshttps://doi.org/10.1360/ssv-2021-0190openalex-snapshot
Immune checkpoint inhibitors in solid tumors
inferred← citeshttps://doi.org/10.14309/ajg.0000000000001983openalex-snapshot
Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management
inferred← citeshttps://doi.org/10.14309/crj.0000000000001018openalex-snapshot
Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
inferred← citeshttps://doi.org/10.14309/crj.0000000000001653openalex-snapshot
Immunomodulators for Steroid-Dependent Recurrent Acute Pancreatitis After Immune Checkpoint Inhibitor Therapy: A Case Series
inferred← citeshttps://doi.org/10.14309/crj.0000000000001878openalex-snapshot
Two Ducts, One Drug—Pembrolizumab-Induced Pancreatic Injury Manifesting as Double-Duct Sign
inferred← citeshttps://doi.org/10.14309/ctg.0000000000000667openalex-snapshot
Incidence of Pancreatic Injury and Pancreatitis in Patients Treated With Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1515/med-2023-0713openalex-snapshot
Immune checkpoint inhibitor-related pancreatitis: What is known and what is not
inferred← citeshttps://doi.org/10.18528/ijgii210052openalex-snapshot
Necrotizing pancreatitis in a COVID-19 patient managed with endoscopic AXIOS stent placement
inferred← citeshttps://doi.org/10.2147/imcrj.s531904openalex-snapshot
Successful Immune Checkpoint Inhibitor Rechallenge After Sintilimab-Induced Pancreatitis: A Case Report
inferred← citeshttps://doi.org/10.2169/internalmedicine.1943-23openalex-snapshot
Immune Checkpoint Inhibitor-induced Pancreatitis with Pancreatic Enlargement Mimicking Autoimmune Pancreatitis: A Case Report and Review of the Literature
inferred← citeshttps://doi.org/10.2169/internalmedicine.5072-24openalex-snapshot
Immune Checkpoint Inhibitor-induced Mass-forming Pancreatitis and Lipodystrophy: A Case Report and Review of the Literature
inferred← citeshttps://doi.org/10.2169/internalmedicine.7366-21openalex-snapshot
Fatal Immune Checkpoint Inhibitor-related Pancreatitis
inferred← citeshttps://doi.org/10.2169/internalmedicine.9565-22openalex-snapshot
Neutrophil Infiltration and Acinar-ductal Metaplasia Are the Main Pathological Findings in Pembrolizumab-induced Pancreatitis
inferred← citeshttps://doi.org/10.2217/imt-2023-0001openalex-snapshot
Gastrointestinal Treatment-Related Adverse Events of Combined Immune Checkpoint Inhibitors: A Meta-Analysis
inferred← citeshttps://doi.org/10.23937/2643-4563/1710032openalex-snapshot
Nivolumab Induced Acute Pancreatitis and Hyperbilirubinemia
inferred← citeshttps://doi.org/10.3329/bmj.v51i3.70143openalex-snapshot
Assessment of Severity of Acute Pancreatitis in Children: Systemic Inflammatory Response Syndrome (SIRS) Score
inferred← citeshttps://doi.org/10.33696/immunology.5.158openalex-snapshot
From Lipase Elevation to Diabetes – Pancreatic Involvement during Immune Checkpoint Inhibition
inferred← citeshttps://doi.org/10.3389/fendo.2021.620522openalex-snapshot
Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
inferred← citeshttps://doi.org/10.3389/fendo.2021.764138openalex-snapshot
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1166299openalex-snapshot
Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1590992openalex-snapshot
Risk factors and long-term prognostic impact of immune related pancreatic injury in patients receiving immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.3389/fonc.2021.627612openalex-snapshot
Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management
inferred← citeshttps://doi.org/10.3389/fonc.2023.1205720openalex-snapshot
Rituximab in steroid-refractory immune-related pancreatitis: a case report
inferred← citeshttps://doi.org/10.3389/fphar.2021.720776openalex-snapshot
Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
inferred← citeshttps://doi.org/10.3389/fphar.2022.817662openalex-snapshot
Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
inferred← citeshttps://doi.org/10.3389/fphar.2022.955701openalex-snapshot
Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fphar.2023.1231320openalex-snapshot
Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
inferred← citeshttps://doi.org/10.3389/fphar.2025.1426847openalex-snapshot
Immune checkpoint inhibitors-induced pancreatitis: a systematic review and real-world pharmacovigilance analysis
inferred← citeshttps://doi.org/10.3389/fphar.2025.1635372openalex-snapshot
Pancreatitis associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database
inferred← citeshttps://doi.org/10.3390/biom12121788openalex-snapshot
Galectin-3 and Myeloperoxidase May Monitor Cancer-Therapy-Related Cardiotoxicity? A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3390/biomedicines14091964openalex-snapshot
Hepatic and Pancreatobiliary Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Multidisciplinary Approach
inferred← citeshttps://doi.org/10.3390/cancers17071080openalex-snapshot
Immune Checkpoint Inhibitor-Induced Pancreatic Injury (ICI-PI) in Adult Cancer Patients: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3390/curroncol30050355openalex-snapshot
Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review
inferred← citeshttps://doi.org/10.3390/curroncol30080554openalex-snapshot
Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications
inferred← citeshttps://doi.org/10.3390/healthcare10050763openalex-snapshot
Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings
inferred← citeshttps://doi.org/10.3390/ijms24087630openalex-snapshot
A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.3390/jcm14093076openalex-snapshot
Autoimmune Pancreatitis: A Review
inferred← citeshttps://doi.org/10.3390/jpm11060566openalex-snapshot
In Situ Delivery and Production System (iDPS) of Anti-Cancer Molecules with Gene-Engineered Bifidobacterium
inferred← citeshttps://doi.org/10.3390/metabo15060385openalex-snapshot
Investigating Immune Checkpoint Inhibitor-Induced Pancreatic Injury: When to Discontinue Cancer Therapy
inferred← citeshttps://doi.org/10.37349/etat.2021.00039openalex-snapshot
Gastrointestinal disorders as immune-related adverse events
inferred← citeshttps://doi.org/10.47892/rgp.2026.461.2062openalex-snapshot
Pancreatitis aguda grave secundaria al uso de inhibidores inmunes de punto de chequeo
inferred← citeshttps://doi.org/10.6004/jnccn.2023.7034openalex-snapshot
Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy
inferred← citeshttps://doi.org/10.7759/cureus.117559openalex-snapshot
Unexpected Acute Pancreatitis After Tarlatamab in Small Cell Lung Cancer: A Case Report
inferred← citeshttps://doi.org/10.7759/cureus.26034openalex-snapshot
Pembrolizumab-Induced Myocarditis and Pancreatitis in a Patient With Colon Cancer: A Case Report
inferred← citeshttps://doi.org/10.7759/cureus.58417openalex-snapshot
Pembrolizumab-Induced Pancreatitis: Take It With a Grain of Salt
inferred← citeshttps://doi.org/10.7759/cureus.68043openalex-snapshot
Immune Checkpoint Inhibitors in Cancer Treatment and Incidence of Pancreatitis
inferred← citeshttps://doi.org/10.7759/cureus.82803openalex-snapshot
Acute Pancreatitis Associated With Blinatumomab Treatment in a Patient With Acute Lymphoblastic Leukemia
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.